Patel Minal R
Department of Health Behavior & Health Equity, University of Michigan School of Public Health, 1415 Washington Heights, SPH 1, Room 3810, Ann Arbor, MI, 48109-2029, USA.
Curr Diab Rep. 2025 May 13;25(1):32. doi: 10.1007/s11892-025-01588-0.
This systematic examination quantifies financial toxicity- the economic burden and related financial distress experienced by patients due to medical costs- in diabetes management globally, analyzing prevalence, mechanisms, and interventions across diverse healthcare systems and geographic contexts.
Data indicates 30-60% of diabetes patients experience financial toxicity, with household expenditures ranging from 5 to 40% of income on disease management, and demographic disparities evident. Current intervention strategies demonstrate limited efficacy, particularly in resource-constrained settings, while policy approaches show mixed results across economic contexts. Financial toxicity operates through four identified pathways: direct expenses, indirect costs (productivity/caregiver burden), insurance coverage limitations, and structural access barriers. Research priorities include developing validated measurement instruments for diabetes financial toxicity, implementing contextually appropriate interventions, and establishing causative relationships between financial burden and clinical outcomes through longitudinal studies.
本系统审查量化了全球糖尿病管理中的经济毒性——即患者因医疗费用而承受的经济负担及相关财务困境，分析了不同医疗体系和地理环境下的患病率、机制及干预措施。
数据表明，30%至60%的糖尿病患者经历过经济毒性，家庭在疾病管理上的支出占收入的5%至40%，且存在明显的人口统计学差异。当前的干预策略效果有限，尤其是在资源有限的环境中，而政策措施在不同经济环境下的效果参差不齐。经济毒性通过四个已确定的途径起作用：直接费用、间接成本（生产力/照护者负担）、保险覆盖范围限制和结构性就医障碍。研究重点包括开发用于衡量糖尿病经济毒性的有效测量工具、实施因地制宜的干预措施，以及通过纵向研究确定财务负担与临床结果之间的因果关系。
